摘要
目的系统评价钠葡萄糖协同转运蛋白2(SGLT2)抑制剂ipragliflozin治疗2型糖尿病(T2DM)的有效性与安全性。方法计算机检索Pubmed、The Cochrane Library、EMbase、CBM和CNKI数据库发表ipragliflozin的文献,筛选合格随机对照试验(RCT)。根据Cochrane系统评价手册5.1评估纳入研究偏倚风险,采用Rev Man 5.3软件进行Meta分析。结果纳入10篇RCTs,共2 390例受试者。结果显示:ipragliflozin较安慰剂更能有效地改善T2DM患者糖化血红蛋白(Hb A1c)水平,同时能降低体质量、血压及空腹血糖(FPG);且不增加低血糖风险,在生殖道感染、泌尿道感染、严重不良事件方面差异无统计学意义。结论 ipragliflozin能有效地改善T2DM患者血糖水平,同时能减轻体质量和降压且安全性好。
Objective To assess the efficacy and safety of ipragliflozin, a sodium glucose cotransporter 2 （SGLT2） inhibitor, for the treatment of type 2 diabetes. Methods Pubmed, the Cochrane Library, EMbase, CBM and CNKI databases was searched to identify randomized controlled trials （RCTs） pertinent to of ipragliflozin. The risk of bias of the included RCTs was assessed according to the Cochrane Handbook for Systematic Reviews of Inter- ventions Version 5.1.The RevMan 5.3 software was used for Meta-analysis. Results Ten RCTs with 2,390 partici- pants were included, Meta analysis showed that ipragliflozin was more effective than placebo in improving HbAlc level, and could concurrently reduce body weight, blood pressure, and the fasting plasma glucose （FPG） but not increase the risk of hypoglycemia. There were no statistically significant differences in the occurrence of urinary tract infection and genital infection as well as serious adverse events. Conclusion As a safe method, ipragliflozin can effectively improve the HbA 1 c level in type 2 diabetes, help patients lose weight and reduce blood pressure.
出处
《实用医学杂志》
CAS
北大核心
2017年第19期3299-3303,共5页
The Journal of Practical Medicine
基金
国家自然科学基金面上项目(编号:8167380)
